Genetic Epidemiology, Translational Neurogenomics, Psychiatric Genetics and Statistical Genetics Laboratories investigate the pattern of disease in families, particularly identical and non-identical twins, to assess the relative importance of genes and environment in a variety of important health problems.
QIMR Home Page
GenEpi Home Page
About GenEpi
Publications
Contacts
Research
Staff Index
Collaborators
Software Tools
Computing Resources
Studies
Search
GenEpi Intranet
PMID
24126065
TITLE
Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season.
ABSTRACT
BACKGROUND NlmCategory: BACKGROUND
Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system which responds to therapies targeting circulating immune cells.
OBJECTIVE NlmCategory: OBJECTIVE
Our aim was to test if the T-cell activation gene expression pattern (TCAGE) we had previously described from whole blood was replicated in an independent cohort.
METHODS NlmCategory: METHODS
We used RNA-seq to interrogate the whole blood transcriptomes of 72 individuals (40 healthy controls, 32 untreated MS). A cohort of 862 control individuals from the Brisbane Systems Genetics Study (BSGS) was used to assess heritability and seasonal expression. The effect of interferon beta (IFNB) therapy on expression was evaluated.
RESULTS NlmCategory: RESULTS
The MS/TCAGE association was replicated and rationalized to a single marker, ribosomal protein S6 (RPS6). Expression of RPS6 was higher in MS than controls (p<0.0004), and lower in winter than summer (p<4.6E-06). The seasonal pattern correlated with monthly UV light index (R=0.82, p<0.002), and was also identified in the BSGS cohort (p<0.0016). Variation in expression of RPS6 was not strongly heritable. RPS6 expression was reduced by IFNB therapy.
CONCLUSIONS NlmCategory: CONCLUSIONS
These data support investigation of RPS6 as a potential therapeutic target and candidate biomarker for measuring clinical response to IFNB and other MS therapies, and of MS disease heterogeneity.
DATE PUBLISHED
2014 May
HISTORY
PUBSTATUS PUBSTATUSDATE
aheadofprint 2013/10/14
entrez 2013/10/16 06:00
pubmed 2013/10/16 06:00
medline 2013/10/16 06:00
AUTHORS
NAME COLLECTIVENAME LASTNAME FORENAME INITIALS AFFILIATION AFFILIATIONINFO
Parnell GP Parnell Grant P GP Westmead Millennium Institute, University of Sydney, Sydney, New South Wales, Australia.
Gatt PN Gatt Prudence N PN
McKay FC McKay Fiona C FC
Schibeci S Schibeci Stephen S
Krupa M Krupa Malgorzata M
Powell JE Powell Joseph E JE
Visscher PM Visscher Peter M PM
Montgomery GW Montgomery Grant W GW
Lechner-Scott J Lechner-Scott Jeannette J
Broadley S Broadley Simon S
Liddle C Liddle Christopher C
Slee M Slee Mark M
Vucic S Vucic Steve S
Stewart GJ Stewart Graeme J GJ
Booth DR Booth David R DR
INVESTIGATORS
JOURNAL
VOLUME: 20
ISSUE: 6
TITLE: Multiple sclerosis (Houndmills, Basingstoke, England)
ISOABBREVIATION: Mult. Scler.
YEAR: 2014
MONTH: May
DAY:
MEDLINEDATE:
SEASON:
CITEDMEDIUM: Internet
ISSN: 1477-0970
ISSNTYPE: Electronic
MEDLINE JOURNAL
MEDLINETA: Mult Scler
COUNTRY: England
ISSNLINKING: 1352-4585
NLMUNIQUEID: 9509185
PUBLICATION TYPE
PUBLICATIONTYPE TEXT
Journal Article
Research Support, Non-U.S. Gov't
COMMENTS AND CORRECTIONS
GRANTS
GENERAL NOTE
KEYWORDS
KEYWORD
Multiple sclerosis
RPS6
biomarkers
interferon beta
season
MESH HEADINGS
SUPPLEMENTARY MESH
GENE SYMBOLS
CHEMICALS
OTHER ID's